Randomized controlled trials of interventions to prevent sexually transmitted infections: Learning from the past to plan for the future

Epidemiologic Reviews

Volumn 32, Issue 1, 2010, Pages 121-136

  Wetmore, Catherine M ^a   Manhart, Lisa E ^a   Wasserheit, Judith N ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

anti infective agents; barrier; circumcision; contraception; male; primary prevention; sexually transmitted diseases; vaccines

Indexed keywords

AZITHROMYCIN; HEPATITIS B VACCINE; MICROBICIDE; TRICHOMONIASIS VACCINE;

CIRCUMCISION; HEALTH SERVICE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; SYSTEMATIC REVIEW; TRICHOMONIASIS; FEMALE; HEALTH; MALE; PRIMARY PREVENTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUALLY TRANSMITTED DISEASES;

FEMALE; GLOBAL HEALTH; HUMANS; MALE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUALLY TRANSMITTED DISEASES;

EID: 77955005102     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxq010     Document Type: Review

References (115)

1. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637-639.
2. US Food and Drug Administration. Food and Drug Administration Modernization Act of 1997. Public Law 105-115, 105th Congress, section 113. DOC ID f:publ115.105. Rockville, MD: Food and Drug Administration; 1997. (http://www.fda.gov/RegulatoryInformation/Legislation/Federal- FoodDrugandCosmeticActFDCAct/SignificantAmendment-stotheFDCAct/FDAMA/ FullTextofFDAMAlaw/default. htm).
3. US National Institutes of Health. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine;2000. (www.ClinicalTrials.gov). (Accessed November 21, 2009).
4. Hallfors DD, Iritani BJ, Miller WC, et al. Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions. Am J Public Health. 2007;97(1): 125-132.
5. Manhart LE, Holmes KK. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? J Infect Dis. 2005;191(suppl 1):S7-S24.
6. Gray RH, Wabwire-Mangen F, Kigozi G, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol. 2001;185(5):1209-1217.
7. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. EXPLORE Study Team. Lancet. 2004; 364(9428):41-50.
8. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chla-mydial infection. N Engl J Med. 1996;334(21):1362-1366. (Pubitemid 26152715)
9. Labbe AC, Dzokoto A, Khonde N. A randomised placebo-controlled trial of routine monthly antibiotics against gono-coccal and chlamydial infections among female sex workers in Ghana and Benin: intention-to-treat analysis. Presented at the 15th Biennial Congress of the International Society for Sexually Transmitted Diseases Research (ISSTDR), Ottawa, Canada, July 27, 2003-July 30, 2007.
10. Koepsell T, Weiss N. Epidemiologic Methods: Studying the Occurrence of Illness. New York, NY: Oxford University Press; 2003.
11. Boyer CB, Barrett DC, Peterman TA, et al. Sexually transmitted disease (STD) and HIV risk in heterosexual adults attending a public STD clinic: evaluation of a randomized controlled behavioral risk-reduction intervention trial. AIDS. 1997;11(3):359-367.
12. Branson BM, Peterman TA, Cannon RO, et al. Group counseling to prevent sexually transmitted disease and HIV: a randomized controlled trial. Sex Transm Dis. 1998;25(10):553-560
13. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. Science. 1998;280(5371):1889-1894.
14. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280(13):1161-1167.
15. Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190(6):1059- 1067.
16. Metcalf CA, Malotte CK, Douglas JM Jr, et al. Efficacy of a booster counseling session 6 months after HIV testing and counseling: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):123-129.
17. Metcalf CA, Douglas JM Jr, Malotte CK, et al. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):130-138.
18. Shain RN, Piper JM, Newton ER, et al. A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women. N Engl J Med. 1999;340(2):93-100.
19. Shain RN, Perdue ST, Piper JM, et al. Behaviors changed by intervention are associated with reduced STD recurrence: the importance of context in measurement. Sex Transm Dis. 2002;29(9):520-529.
20. Shain RN, Piper JM, Holden AE, et al. Prevention of gonorrhea and Chlamydia through behavioral intervention: results of a two-year controlled randomized trial in minority women. Sex Transm Dis. 2004;31(7):401-408
21. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Lancet. 2000;356(9224): 103-112.
22. Hobfoll SE, Jackson AP, Lavin J, et al. Effects and general-izability of communally oriented HIV-AIDS prevention versus general health promotion groups for single, inner-city women in urban clinics. J Consult Clin Psychol. 2002;70(4): 950-960.
23. Baker SA, Beadnell B, Stoner S, et al. Skills training versus health education to prevent STDs/HIV in heterosexual women: a randomized controlled trial utilizing biological outcomes. AIDS Educ Prev. 2003;15(1):1-14.
24. Kamali A, Quigley M, Nakiyingi J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet. 2003; 361(9358):645-652.
25. DiClemente RJ, Wingood GM, Harrington KF, et al. Efficacy of an HIV prevention intervention for African American adolescent girls: a randomized controlled trial. JAMA. 2004; 292(2):171-179.
26. Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: the WiLLOW Program. J Acquir Immune Defic Syndr. 2004;37(suppl 2):S58-S67.
27. Downs JS, Murray PJ, Bruine de Bruin W, et al. Interactive video behavioral intervention to reduce adolescent females' STD risk: a randomized controlled trial. Soc Sci Med. 2004; 59(8):1561-1572.
28. Artz L, Macaluso M, Meinzen-Derr J, et al. A randomized trial of clinician-delivered interventions promoting barrier contraception for sexually transmitted disease prevention. Sex Transm Dis. 2005;32(11):672-679.
29. Boyer CB, Shafer MA, Shaffer RA, et al. Evaluation of a cognitive-behavioral, group, randomized controlled intervention trial to prevent sexually transmitted infections and unintended pregnancies in young women. Prev Med. 2005; 40(4):420-431.
30. Feldblum PJ, Hatzell T, Van Damme K, et al. Results of a randomised trial of male condom promotion among Madagascar sex workers. Sex Transm Infect. 2005;81(2): 166-173.
31. Hoke TH, Feldblum PJ, Damme KV, et al. Randomised controlled trial of alternative male and female condom promotion strategies targeting sex workers in Madagascar. Sex Transm Infect. 2007;83(6):448-453.
32. Jemmott JB III, Jemmott LS, Braverman PK, et al. HIV/STD risk reduction interventions for African American and Latino adolescent girls at an adolescent medicine clinic: a randomized controlled trial. Arch Pediatr Adolesc Med. 2005;159(5): 440-449.
33. Jemmott LS, Jemmott JB III, O'Leary A. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings. Am J Public Health. 2007;97(6): 1034-1040.
34. Jewkes R, Nduna M, Levin J, et al. Impact of Stepping Stones on incidence of HIVand HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. BMJ. 2008;337:391-395.
35. Patterson TL, Mausbach B, Lozada R, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health. 2008;98(11):2051-2057.
36. Peipert JF, Redding CA, Blume JD, et al. Tailored intervention to increase dual-contraceptive method use: a randomized trial to reduce unintended pregnancies and sexually transmitted infections. Am J Obstet Gynecol. 2008;198(6):630.e1-630.e8.
37. Warner L, Klausner JD, Rietmeijer CA, et al. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med. 2008;5(6):e135. (doi:10.1371/journal.pmed.0050135). (Pubitemid 351919113)
38. Crosby R, DiClemente RJ, Charnigo R, et al. A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. Am J Public Health. 2009;99(suppl 1): S96-S103.
39. Grimley DM, Hook EW III. A 15-minute interactive, computerized condom use intervention with biological endpoints. Sex Transm Dis. 2009;36(2):73-78.
40. Marion LN, Finnegan L, Campbell RT, et al. The Well Woman Program: a community-based randomized trial to prevent sexually transmitted infections in low-income African American women. Res Nurs Health. 2009;32(3): 274-285.
41. Fontanet AL, Saba J, Chandelying V, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS. 1998; 12(14):1851-1859.
42. Feldblum PJ, Kuyoh MA, Bwayo JJ, et al. Female condom introduction and sexually transmitted infection prevalence: results of a community intervention trial in Kenya. AIDS. 2001;15(8):1037-1044.
43. Steiner MJ, Hylton-Kong T, Figueroa JP, et al. Does a choice of condoms impact sexually transmitted infection incidence? A randomized, controlled trial. Sex Transm Dis. 2006;33(1): 31-35.
44. Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One. 2008;3(10):e3488. (doi:10.1371/journal.pone. 0003488).
45. Sawaya GF, Chirenje MZ, Magure MT, et al. Effect of diaphragm and lubricant gel provision on human papillomavi-rus infection among women provided with condoms: a randomized controlled trial. Obstet Gynecol. 2008;112(5): 990-997.
46. Cutler JC, Singh B, Uri C, et al. Vaginal contraceptive as prophylaxis against gonorrhea and other sexually transmissible diseases. Adv Plan Parent. 1977;12:45-56.
47. Rendon AL, Covarrubias J, McCarney KE, et al. A controlled comparative study of phenylmercuric acetate, nonoxynol-9 and placebo vaginal suppositories as prophylactic agents against gonorrhea. Curr Ther Res. 1980;27:780-783.
48. Rosenberg MJ, Rojanapithayakorn W, Feldblum PJ, et al. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial. JAMA. 1987;257(17):2308-2312.
49. Louv WC, Austin H, Alexander WJ, et al. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis. 1988;158(3):518-523.
50. Niruthisard S, Roddy RE, Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet. 1992;339(8806):1371-1375.
51. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268(4): 477-482.
52. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339(8): 504-510.
53. Richardson BA, Lavreys L, Martin HL Jr, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28(7):394-400.
54. Roddy RE, Zekeng L, Ryan KA, et al. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA. 2002;287(9):1117-1122.
55. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971-977.
56. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5): 463-472.
57. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One. 2008;3(11):e3784. (doi:10.1371/journal.pone.0003784) .
58. Mattson CL, Campbell RT, Bailey RC, et al. Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS One. 2008;3(6):e2443. (doi:10.1371/journal.pone.0002443).
59. Mehta SD, Moses S, Agot K, et al. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J Infect Dis. 2009;200(3):370-378.
60. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, et al. Male circumcision and Neisseria gonorrhoeae, Chlamydia tra-chomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex Transm Infect. 2009;85(2):116-120.
61. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009;199(1):14-19.
62. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009;360(13):1298-1309.
63. Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2009;200(1):42e.1-42e.7.
64. Lyng J, Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand. 1981; 60(2):199-201.
65. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis. 2003;30(1):49-56.
66. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005; 352(7):676-685.
67. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis. 2005;41(5): 623-629.
68. Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33(7):445-450.
69. Cameron ST, Glasier A, Scott G, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. Hum Reprod. 2009;24(4):888-895.
70. Wilson TE, Hogben M, Malka ES, et al. A randomized controlled trial for reducing risks for sexually transmitted infections through enhanced patient-based partner notification. Am J Public Health. 2009;99(suppl 1):S104-S110.
71. Harrison WO, Hooper RR, Wiesner PJ, et al. A trial of minocycline given after exposure to prevent gonorrhea. N Engl J Med. 1979;300(19):1074-1078.
72. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 1999;353(9152):525-535.
73. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA. 2004;291(21):2555-2562.
74. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008;197(10):1361-1368.
75. Schwebke JR, Desmond R. A randomized trial of metroni-dazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196(6):517.e1-517e.6.
76. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11-20.
77. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995; 346(8974):530-536.
78. Mayaud P, Mosha F, Todd J, et al. Improved treatment services significantly reduce the prevalence of sexually transmitted diseases in rural Tanzania: results of a randomized controlled trial. AIDS. 1997;11(15):1873-1880.
79. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303(15):833-841.
80. Szmuness W, Stevens CE, Zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hep-tavax B): a final report. Hepatology. 1981;1(5):377-385. (Pubitemid 12218155)
81. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control Multi-Center Efficacy Trial among homosexual men. Ann Intern Med. 1982;97(3):362-366.
82. Coutinho RA, Lelie N, Albrecht-Van Lent P, et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed). 1983;286(6374):1305-1308.
83. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med. 1997;157(14):1537- 1544.
84. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999;282(4):331-340.
85. Stanberry LR, Spruance SL, Cunningham AL, et al. Glyco-protein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652-1661.
86. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
87. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364 (9447):1757-1765.
88. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
89. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. GlaxoS-mithKline Vaccine HPV-007 Study Group. Lancet. 2009; 374(9706):1975-1985.
90. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580): 2161-2170.
91. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686): 301-314.
92. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278.
93. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459- 1466.
94. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19): 1928-1943. (Pubitemid 46740303)
95. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
96. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196(10):1438-1446.
97. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574): 1693-1702.
98. Barr E, Gause CK, Bautista OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008;198(3):261.e1-261.e11.
99. Tay EH, Garland S, Tang G, et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet. 2008;102(3):275-283.
100. Muñoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papil-lomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949-1957.
101. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199(7): 936-944.
102. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199(7):926-935.
103. Ross DA, Changalucha J, Obasi AI, et al. Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial. AIDS. 2007;21(14):1943-1955.
104. NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. Eban HIV/STD risk reduction intervention: conceptual basis and procedures. J Acquir Immune Defic Syndr. 2008;49(suppl 1):S15-S27
105. NIMH Collaborative HIV/STD Prevention Trial Group. Methodological overview of a five-country community-level HIV/sexually transmitted disease prevention trial. AIDS. 2007;21(suppl 2):S3-S18.
106. Karim SA, Coletti A, Richardson BA. Safety and effectiveness of vaginal microbicides BufferGel and PRO 2000 gel for the prevention of HIV infection in women. Presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada, February 8, 2009-February 11, 2009.
107. Microbicides Development Programme. HIV 'Prevention' gel PRO 2000 Proven Ineffective. London, United Kingdom: UK Medical Research Council and Imperial College London; 2009.
108. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298. (doi:10.1371/journal.pmed.0020298). (Pubitemid 41735779)
109. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643-656.
110. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657-666.
111. Golden MR, Wasserheit JN. Prevention of viral sexually transmitted infections\foreskin at the forefront. N Engl J Med. 2009;360(13):1349-1351.
112. Cowan FM, Pascoe SJ, Langhaug LF, et al. The Regai Dzive Shiri Project: a cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe\study design and baseline results. Trop Med Int Health. 2008;13(10):1235-1244.
113. Garcia PJ, Holmes KK, Garnett GP. The PREVEN Project: urban community randomized trial of a multicomponent intervention for prevention of STI in Latin America. Presented at the 18th Meeting of the International Society for STD Research (ISSTDR) in Conjunction With the British Association for Sexual Health and HIV (BASHH), London, United Kingdom, June 30, 2009.
114. Padian NS, McCoy SI, Balkus JE, et al. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24(5):621-635.
115. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York, NY: Oxford University Press; 2000.